Abstract:BackgroundAn ageing population and lifestyle changes have led to increased cardiovascular disease-related morbidity and mortality in China, where an estimated 230 million people have cardiovascular disease. Long-term antiplatelet therapy with aspirin and clopidogrel are used for treatment and post-stenting primary prevention of acute coronary syndrome, but the risk of bleeding complications is high. This study aimed to identify the target of the newly developed antiplatelet agent ADTM, originating from traditional Chinese herbs. We also investigated the antiplatelet and cardioprotective effects of ADTM.MethodsWe developed ADTM by conjugating danshensu and tetramethylpyrazine, which are active compounds in the herbs danshen (Salvia miltiorrhizae) and chuanxiong (Ligustium wallichii Franch), respectively. To identify the target of ADTM, we incubated its biotinylated analogue with rat blood platelet lysates, then used chemical proteomics to precipitate protein complexes. We compared the antiplatelet effect of ADTM with clopidogrel in a rat model in vivo by administrating ADTM (5–20 mg/kg) and clopidogrel (18 mg/kg) intravenously daily for 5 days, and inducing platelet aggregation by adenosine diphosphate. We also assessed the inhibitory effects of ADTM and clopidogrel on ferric chloride (FeCl3)-induced venous thrombus formation. We further assessed the cardioprotective effects of ADTM in a canine coronary artery occlusion-reperfusion model. The left anterior descending coronary artery was occluded for 20 min followed by reperfusion in five beagles (weighing about 12 kg). 15 min after occlusion, ADTM (6mg/kg) or nitroglycerin (45 μg) was administered for 3 min continuously.FindingsResults of chemical proteomics showed that ADTM targets ERp57. The inhibitory effects of ADTM on platelet aggregation were similar to clopidogrel in the rat model (mean 40% [SD 11] for ADTM [p=0·018 vs control] and 38% [9] for clopidogrel [p=0·0073 vs control; p=0·78 vs ADTM). Similarly, the inhibitory effects on FeCl3-induced venous thrombus formation were 50% (SD 10) for ADTM (p=0·0087 vs vehicle control) and 42% (6) for clopidogrel (p=0·0093 vs vehicle control; p=0·85 vs ADTM). ADTM increased mean coronary blood flow by 36% (SD 15; p=0·0165 for before vs after ADTM administration) and decreased mean arterial pressure (MAP) from 102 mm Hg (2·7) to 96 mm Hg (1·3; p=0·0031). Coronary blood flow did not differ between before and after nitroglycerin administration (p=0·49), but nitroglycerin did decrease mean arterial pressure from 102 mm Hg (1·6) to 92 mm Hg (1·5; p=0·0076). ADTM and nitroglycerin reduced the infarct size of cardiac tissue by a mean of 10% (SD 3; p=0·0217) and 8% (2; p=0·0072), respectively.InterpretationADTM is a ligand that targets ERp57 and displays antiplatelet and cardioprotective effects in animal models. ADTM represents a potential lead compound for further investigation and development of new antiplatelet drugs with reduced bleeding risk.FundingThe National Natural Science Foundation of China (NSFC-81403139) and University of Macau (MYRG2015-00161-ICMS-QRCM).

Correction: Corrigendum: Novel Anti-Thrombotic Agent for Modulation of Protein Disulfide Isomerase Family Member ERp57 for Prophylactic Therapy

Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy

Identification of disulfide isomerase ERp57 as a target for small molecule cardioprotective agents

Development of the Novel Antiplatelet Agent ADTM, Originating from Traditional Chinese Medicine: a Chemical Proteomic Analysis and In-Vivo Assessment of Efficacy in an Animal Model

A novel Danshensu derivative confers cardioprotection via PI3K/Akt and Nrf2 pathways

Pharmacokinetic and Metabolic Studies of ADTM: A Novel Danshensu Derivative Confers Cardioprotection by HPLC-UV and LC-MS/MS.

Discovery of a Novel ERp57 Inhibitor As Antiplatelet Agent from Danshen (salvia Miltiorrhiza)

Design, Synthesis and Biological Evaluation of Novel Trimethylpyrazine-2-carbonyloxy-cinnamic Acids As Potent Cardiovascular Agents

Modulation Of Platelet Activation And Thrombus Formation Using A Pan-Pi3k Inhibitor S14161

Cardioprotection of a Novel Danshensu Derivate Against Oxidative Injury and Mitochondrial Dysfunction in Vitro and Myocardial Ischemia/Reperfusion Injury in Rat

Design, synthesis, and preliminary cardioprotective effect evaluation of danshensu derivatives.

Synthesis and Biological Evaluation of Danshensu and Tetramethylpyrazine Conjugates As Cardioprotective Agents

Molecular Docking‐assisted Screening Reveals Tannic Acid As a Natural Protein Disulphide Isomerase Inhibitor with Antiplatelet and Antithrombotic Activities

Design, synthesis and cardioprotective effect of a new class of dual-acting agents: Phenolic tetrahydro-β-carboline RGD peptidomimetic conjugates

Recent advances in vascular thiol isomerases and redox systems in platelet function and thrombosis

Correction: Corrigendum: Adiponectin-derived active peptide ADP355 exerts anti-inflammatory and anti-fibrotic activities in thioacetamide-induced liver injury

Protosappanin a protects DOX-induced myocardial injury and cardiac dysfunction by targeting ACSL4/FTH1 axis-dependent ferroptosis

Synergistic cardioprotective effects of Danshensu and hydroxysafflor yellow A against myocardial ischemia-reperfusion injury are mediated through the Akt/Nrf2/HO-1 pathway Corrigendum in /10.3892/ijmm.2021.5045

Design, Synthesis And Biological Evaluation Of Hydrogen Sulfide Releasing Derivatives Of 3-N-Butylphthalide As Potential Antiplatelet And Antithrombotic Agents

A Novel Danshensu/tetramethylpyrazine Derivative Induces Vasorelaxation on Rat Aorta and Exerts Cardioprotection in Dogs

Platelet Endothelial Cell Adhesion Molecule Targeted Oxidant-Resistant Mutant Thrombomodulin Fusion Protein with Enhanced Potency in Vitro and in Vivo.